ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis

Affiliations

¹ Department of Dermatology, University Hospital of Basel, Basel, Switzerland.
² Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
³ Department of Clinical Research, University c/o University Hospital of Basel, Basel, Switzerland.
⁴ Department of Dermatology, University Hospital of Bern, Bern, Switzerland.
⁵ Department of Dermatology, University Hospital of Lausanne, Lausanne, Switzerland.
⁶ Department of Dermatology, Plaza Klinik, Uster, Switzerland.
⁷ Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁸ Department of Dermatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Sara E Cerminara et al. J Eur Acad Dermatol Venereol. 2025 May.

. 2025 May;39(5):e424-e426.

doi: 10.1111/jdv.20400. Epub 2024 Oct 24.

¹ Department of Dermatology, University Hospital of Basel, Basel, Switzerland.
² Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
³ Department of Clinical Research, University c/o University Hospital of Basel, Basel, Switzerland.
⁴ Department of Dermatology, University Hospital of Bern, Bern, Switzerland.
⁵ Department of Dermatology, University Hospital of Lausanne, Lausanne, Switzerland.
⁶ Department of Dermatology, Plaza Klinik, Uster, Switzerland.
⁷ Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁸ Department of Dermatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

No abstract available

References

1. Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.
1. Carrascosa JM, Del‐Alcazar E. Apremilast for psoriasis treatment. G Ital Dermatol Venereol. 2020;155(4):421–433.
1. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
1. Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult‐to‐treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142.
1. Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37(2):348–355.